NCT00767676已完成1 期
Evaluation of the Contact Sensitization Potential of 828 Ointment in Normal Healthy Adults
适应症
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- Healthpoint
- 入组人数
- 259
- 试验地点
- 2
- 主要终点
- Number of Participants That Exhibited a Score Less Than 1.5 on the Jordan-King Scale
研究概览
简要总结
Contact sensitization by patch applications.
详细描述
Single site study that will evaluate the contact sensitization potential of 828 ointment by repetitive patch applications to the skin of normal, healthy volunteers.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 盲法
- Single (Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 65 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Subjects must satisfy all of the following criteria:
- •Subjects must be ambulatory, 18 to 65 years of age and in reasonably good health (no physical required).
- •Subjects may be of any race or skin type provided their skin pigmentation does not interfere with evaluations.
- •Female subjects must be surgically sterile, post-menopausal or using an acceptable method of birth control.
- •Minor deviations in normal medical history not considered to be clinically significant by the investigator and the sponsor will be permitted.
- •Subjects must refrain from sunbathing, using tanning salons, swimming, or using hot tubs during the entire study.
- •Bathing is permitted but subjects must agree to try and keep the patches as dry as possible.
- •Subjects must read and sign the informed consent statement.
- •All females of child bearing potential must agree to take an entry and exit urine pregnancy test
排除标准
- •Subjects with any of the following conditions are not eligible for participation:
- •Any systemic disease or disorder, complicating factors or structural abnormality that would negatively affect the conduct or outcome of the study (i.e., hepatitis, acute or chronic renal insufficiency).
- •Use of a prescribed pain medication, prescribed or over-the-counter anti-inflammatory drugs, immunosuppressive drugs or prescribed antihistamine medication (steroid nose drops and/or eye drops are permitted). Use of any over-the-counter pain medication that is ingested in quantities exceeding label instructions.
- •Subjects who have received an investigational drug or have participated in a Draize type patch test within the past 28 days or who are currently participating in or plan to enter a clinical trial.
- •A history of non-compliance or subjects who are considered potentially unreliable.
- •A history of skin allergies, including known sensitivity or strong reactions to any cosmetics and/or personal care products, topically prepared medical dressings, tapes, or adhesives.
- •A history of clinically significant skin diseases which may contraindicate participation, including psoriasis, active eczema (at the test sites), atopic dermatitis, and active cancer, even if currently controlled through medication.
- •Current use of topical or oral antibiotics.
- •Use of topical medications at the test area 2 weeks prior to enrollment or any body lotions/oils/creams at the test area for 48 hours prior to enrollment and throughout the trial.
- •Female subjects who are pregnant, stop contraceptive measures, expect to become pregnant or who are breast-feeding.
- •Subjects with any condition known to interfere with the absorption, distribution, metabolism, or excretion of drugs.
- •Subjects with hematological disorders or immunologic disorders (HIV positive, AIDS, and Systemic Lupus Erythematosus).
- •Subjects with any significant organ abnormality or disorders including gastric ulcer/insulin dependent diabetes.
- •Subjects with any clinically significant illness (sought medical attention, fever, took prescription medication) within the 4 weeks prior to study entry.
- •History of asthma, chronic bronchitis or any other bronchospastic condition that requires medication.
- •Anticipated change in the use of a systemic medication during the study that may affect the conduct or outcome of the study. Subjects must be stabilized on these medications for a least one month prior to receiving study drug and continue same regimen throughout the study.
- •Bilateral mastectomy for cancer involving removal of lymph nodes.
- •Treatment of any type of cancer within the last six months.
- •The Investigator may declare any subject ineligible for a sound medical reason.
- •Subjects with allergies/known sensitivities to any of the ingredients of the test article.
结局指标
主要结局
Number of Participants That Exhibited a Score Less Than 1.5 on the Jordan-King Scale
时间窗: 7 weeks
To qualify for the claim of a reduced sensitization potential, all subjects completing the study could exhibit a value of no more than 1.5 on the Jordan-King Scale \[scale is 0 (no visible reaction) to 5 (severe erythema)\] No statistical analyses were performed.
次要结局
未报告次要终点
研究者
研究点 (2)
Loading locations...
相似试验
已完成
1 期
Human Repeat Insult Patch Test of Wound DressingsSkin SensitizationNCT01368146Covalon Technologies Inc.216
已完成
1 期
Safety Study to Evaluate the Contact Sensitizing Potential of Topically Applied ZuraPrep™ and ZuraPrep™ Without IPASurgical Site InfectionNCT02160587Zurex Pharma, Inc.208
招募中
不适用
SPT for Sensitization of Collagen DressingAllergy SkinAllergic Skin ReactionNCT06271993Covalon Technologies Inc.30
已完成
1 期
Skin Sensitization Potential of a New Nicotine PatchSmoking CessationNCT00967070McNeil AB257
招募中
不适用
A Prospective Study to Investigate Contact Sensitization Using Classic and Machine Learning TechniquesAllergic Contact DermatitisNCT05991674Andreas Syggros Hospital of Venereal and Dermatological Diseases80